- ByInvesting.com-
Investing.com -- UBS Switzerland AG’s Chief Investment Office expects sustained positive earnings growth for Swiss equities...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 130.40 | 133.90 | 130.10 | -0.70 | -0.53% | 2.23M | ||
| 64.46 | 66.58 | 64.12 | -1.38 | -2.10% | 6.07M | ||
| 63.66 | 65.58 | 63.32 | +1.06 | +1.69% | 7.04M | ||
| 69.90 | 72.06 | 69.90 | -1.22 | -1.72% | 2.1M | ||
| 540.80 | 552.80 | 540.80 | -4.20 | -0.77% | 1.12M | ||
| 823.80 | 845.20 | 823.40 | -7.60 | -0.91% | 130.4K | ||
| 115.60 | 117.98 | 115.22 | -1.28 | -1.10% | 10.92M | ||
| 75.86 | 76.93 | 75.86 | -0.77 | -1.00% | 8.99M | ||
| 128.00 | 130.50 | 128.00 | -1.45 | -1.12% | 2.18M | ||
| 300.90 | 309.50 | 300.90 | -4.80 | -1.57% | 3.79M | ||
| 466.70 | 480.20 | 466.70 | -6.60 | -1.39% | 297.42K | ||
| 687.00 | 704.00 | 687.00 | -17.50 | -2.48% | 596.5K | ||
| 525.60 | 534.80 | 525.60 | -1.60 | -0.30% | 235.83K | ||
| 126.90 | 129.35 | 126.45 | +0.55 | +0.44% | 3.24M | ||
| 793.20 | 813.60 | 790.60 | -10.00 | -1.25% | 436.94K | ||
| 167.00 | 171.45 | 167.00 | -3.50 | -2.05% | 1.4M | ||
| 29.08 | 29.69 | 28.82 | -0.19 | -0.65% | 23.33M | ||
| 2,678.00 | 2,719.00 | 2,678.00 | -23.00 | -0.85% | 123.04K | ||
| 58.22 | 59.66 | 58.22 | -1.26 | -2.12% | 2.01M | ||
| 41.87 | 43.43 | 41.72 | -0.45 | -1.06% | 6.22M |
Investing.com -- UBS Switzerland AG’s Chief Investment Office expects sustained positive earnings growth for Swiss equities...
Investing.com -- DocMorris AG (SIX:DOCM) on Thursday posted adjusted EBITDA of CHF -50 million for fiscal year 2025, falling...
Investing.com -- Swissquote Group Holding Ltd (SIX:SQN) on Thursday reported fiscal year 2025 results in line with consensus...
Equity futures point higher, but bond market stress and gold strength keep risk appetite cautious. Policy relief sparks a sharp...
Amphastar Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company known for developing, manufacturing, and...
Want to hear something really scary? The ongoing government shutdown, now in its second month, is projected to cost the U.S....
No Earning Reports have been scheduled